Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13257724 | 1.00 | CYP2D6 (0.52) | CYP2D6SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL16510079 | 1.00 | CYP2D6 (0.52) | CYP2D6SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL10747371 | 0.84 | PDE10A (0.46) | CYP2D6SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL1692219 | 0.84 | SLC6A2 (0.53) | CYP2D6SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL25259107 | 0.84 | CYP2D6 (0.38) | CYP2D6SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL2293905 | 0.82 | PDE10A (0.47) | CYP2D6KCNH2CHRM1DRD3CYP1A2 | |
| SCHEMBL2298028 | 0.82 | PDE10A (0.47) | SLC6A3DRD3 | |
| SCHEMBL24394471 | 0.82 | PDE10A (0.47) | CYP2D6KCNH2CHRM1DRD3CYP1A2 | |
| SCHEMBL2298311 | 0.82 | DRD3 (0.41) | CYP2D6SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL2294863 | 0.82 | DRD3 (0.41) | CYP2D6SLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113135835-A | Method for exciting C-C bond breaking acylation and application | 广州中医药大学(广州中医药研究院) | 2021-07-20 | — | — | CN | claimed |
| EP-0543919-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES. | SEARLE & CO (US) | 1993-06-02 | — | — | EP | claimed |
| WO-2024081363-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230276802-A1 | Method for Controlling Hematophagous or Sap-Feeding Arthropods | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSTIY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| WO-2023141511-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11632953-B2 | Method for controlling hematophagous or sap-feeding arthropods | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2023-04-25 | — | — | US | disclosed |
| WO-2023064585-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064584-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| EP-1740574-B1 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| CN-1863514-A | Abuse-proffed dosage form | GRUENENTHAL GMBH (DE) | 2006-11-15 | — | — | CN | disclosed |
| CN-1863513-A | Abuse-proffed dosage form | GRUENENTHAL GMBH (DE) | 2006-11-15 | — | — | CN | disclosed |
| CN-1179418-A | Novel cyloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | HOECHST AG (DE) | 1998-04-22 | — | — | CN | disclosed |
| EP-0543919-A1 | USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS FOR TREATMENT OF CNS DISEASES. | SEARLE & CO (US) | 1993-06-02 | — | — | EP | disclosed |
| EP-0080940-B1 | DERIVATIVES OF 2-PHENYL-MORPHOLINE AND MEDICAL COMPOSITIONS | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1986-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11632953-B2 | Method for controlling hematophagous or sap-feeding arthropods | KCNN1, KCNN2, KCNN3 | CYP2D6 3966/4885SLC6A2 877/4885SLC6A4 2232/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | CYP2D6 4714/4885SLC6A2 4621/4885SLC6A4 4514/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CYP2D6 3178/4885SLC6A2 4833/4885SLC6A4 4820/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | CYP2D6 407/4885SLC6A2 3741/4885SLC6A4 3049/4885 |
| US-20230276802-A1 | Method for Controlling Hematophagous or Sap-Feeding Arthropods | KCNN1, KCNN2, KCNN3 | CYP2D6 3966/4885SLC6A2 877/4885SLC6A4 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.